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PROGRESS REPORT ON CDC’S ID FRAMEWORK 
October 2011 – May 2013 
INTRODUCTION 
A CDC Framework for Preventing Infectious Diseases:  Sustaining the Essentials and Innovating for the 
Future (CDC’s ID Framework) was issued in October 2011 as a roadmap for improving our ability to 
prevent known infectious diseases and to recognize and control rare, highly dangerous, and newly 
emerging threats.  Although its primary purpose is to guide CDC’s infectious disease activities, the 
document was also designed to guide collective public health action at a time of resource constraints 
and difficult decisions, while advancing opportunities to improve the nation’s health. 
This Progress Report is intended to provide a brief update on the status of CDC’s work since October 
2011 to advance the three elements of the ID Framework: 
 Strengthen public health fundamentals, including infectious disease surveillance, laboratory 
detection, and epidemiologic investigation 
 Identify and implement high-impact public health interventions to reduce infectious diseases 
 Develop and advance policies to prevent, detect, and control infectious diseases 
Over the past year, CDC programs in the National Center for Emerging and Zoonotic Infectious 
Diseases (NCEZID); National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
(NCHHSTP); National Center for Immunization and Respiratory Diseases (NCIRD); and Center for 
Global Health (CGH) have made significant progress in preventing and controlling infectious 
diseases.  This Progress Report provides a few, selected examples of these accomplishments, 
organized by Framework element.  The examples illustrate how CDC is creating new partnerships 
and using new ideas and scientific findings to advance public health goals.  They also reflect the 
broad range of infectious disease issues addressed by CDC and its public and private partners, 
including the issues of special concern highlighted in the ID Framework:  antimicrobial resistance, 
chronic viral hepatitis, food safety, healthcare-associated infections (HAIs), HIV/AIDS, respiratory 
infections, safe water, vaccine-preventable diseases, and zoonotic and vectorborne diseases.  The 
Progress Report also provides examples of ongoing work in areas that involve new directions, 
alliances, and innovations, a particular need highlighted in the ID Framework.  
More comprehensive information on CDC’s infectious disease accomplishments and activities is 
available through the following websites and reports: 
 CDC Vital Signs and Public Health Grand Rounds websites (Box 1) 
 NCEZID:  Our Work, Our Stories 2011–2012 
 NCHHSTP Annual Report 2012 
 CDC Global Health Strategy 2012–2015. 
A report on CDC’s laboratory activities, including infectious disease laboratory activities, is 
available at http://www.cdc.gov/osels/lspppo/senate_report.html. 
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Box 1.   CDC Public Health Grand Rounds 
The CDC Public Health Grand Rounds is a monthly webcast created to foster discussion on major public 
health issues.  Each session focuses on key challenges related to a specific health topic, and explores 
cutting-edge scientific evidence and the potential impact of different interventions. 
Recent CDC Grand Rounds that have addressed infectious disease topics include the following: 
 Explaining the Unexplained:  Discovering New Diseases Using Advanced Detection Tools.  As our 
world increases in interconnectivity of both technology and people, the rapid identification of 
emerging infectious diseases becomes more important for disease treatment, control, and 
prevention.  CDC has an ongoing role in the laboratory diagnosis of infectious illnesses and 
collaborates 24/7 with state, local, and international partners to track emerging pathogens and 
explain the unexplained. 
Video available at http://www.cdc.gov/about/grand-rounds/archives/2012/September2012.htm 
 High-Impact HIV Prevention.   Recent scientific breakthroughs in prevention, treatment, and 
monitoring disease have provided new tools for HIV/AIDS prevention.  CDC’s High-Impact HIV 
Prevention initiative seeks the most effective distribution of limited resources to bring these tools to 
affected communities.  This initiative advances the implementation of the National HIV/AIDS Strategy 
to improve HIV prevention and care. 
Video available at http://www.cdc.gov/about/grand-rounds/archives/2012/August2012.htm 
 Unsafe Injection Practices in the U.S Healthcare System.  Unsafe injection practices that put patients 
at risk of infection are associated with a wide variety of healthcare procedures and settings.  CDC is 
working with medical and public health partners to improve injection safety. 
Video available at http://www.cdc.gov/about/grand-rounds/archives/2012/November2012.htm 
 The Growing Threat of Multidrug-Resistant Gonorrhea.  The bacteria that cause gonorrhea—
Neisseria gonorrhoeae—have progressively developed resistance to antibiotic drug treatments, 
including sulfonilamides, penicillin, tetracycline, and ciprofloxacin.  Currently, CDC treatment 
guidelines recommend dual therapy with a cephalosporin antibiotic (ceftriaxone is preferred) and 
either azithromycin or doxycycline.  CDC and partners are working together to monitor emerging 
antibiotic resistance in N. gonorrhoeae and encourage research and development of new treatment 
regimens. 
Video available at http://www.cdc.gov/about/grand-rounds/archives/2012/May2012.htm 
 Reducing the Burden of Human Papillomavirus (HPV)-associated Cancer and Disease through 
Vaccination.  An estimated 26,000 HPV-attributable cancers occur in the United States each year, 
including cervical cancers in women and oropharyngeal cancers in men.  HPV vaccine has been 
recommended for routine vaccination of 11–12-year-old girls since 2006 and for 11–12-year-old boys 
since 2011. 
Video available at http://www.cdc.gov/about/grand-rounds/archives/2013/february2013.htm 
 Childhood Immunization as a Tool to Address Health Disparities.  Immunization has helped reduce 
infectious disease disparities among U.S. children, contributing to health equity across race/ethnicity.  
Video available at http://www.cdc.gov/about/grand-rounds/archives/2013/April2013.htm 
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EXAMPLES OF INFECTIOUS DISEASE ACCOMPLISHMENTS 
Element 1. Strengthen public health fundamentals, including infectious disease 
surveillance, laboratory detection, and epidemiologic investigation 
Strong public health fundamentals at the local, state, and national levels—including disease 
surveillance, laboratory detection, and epidemiologic investigation—are the bedrock of U.S. capacity 
to protect the public from infectious diseases and to save lives during outbreaks and other unusual 
health events. 
Efforts to sustain and strengthen public health fundamentals include modernizing infectious disease 
surveillance to drive public health action, expanding the role of public health and clinical 
laboratories in disease control and prevention, building capacity for epidemiologic investigations 
and public health response, and advancing workforce development and training. 
Examples of ID Accomplishments 
 Helped ensure that HIV-infected patients receive ongoing and effective care, by implementing a 
new strategy for monitoring HIV, based on reporting and use of CD4 cell counts and viral loads.  
Partners include state and local health departments and the Health Resources and Services 
Administration. 
 Expanded nationwide surveillance for HAIs, antimicrobial drug use, and adverse reactions 
associated with blood and blood products by creating new surveillance modules for the National 
Healthcare Safety Network.  The HAI modules monitor a wide range of infections in a variety of 
healthcare settings. 
 Improved the detection and control of imported TB cases—including drug-resistant cases—by 
revising procedures for contact-tracing commercial aviation passengers during extended flights. 
The new procedures are expected to reduce the number of contact investigations by 
approximately 50% while still enabling effective detection of infected passengers. 
 Made nationwide collection of infectious disease data faster, cheaper, and more accurate by 
increasing to 54% the percentage of clinical and public health facilities that use electronic 
laboratory reporting (ELR) to report nationally notifiable diseases. 
 Created an interactive, web-based tool—the NCHHSTP Atlas—that allows public access to 
surveillance data on HIV/AIDS, viral hepatitis, STDs, and TB.  State and local health 
departments can use this tool to observe geographic patterns and local trends by creating 
detailed reports, maps, and other graphics.  CDC also issued guidelines for data security and 
confidentiality for the collection, storage, sharing, and use of information on these diseases.  
 Strengthened CDC laboratory capacity to respond to large-scale infectious disease events by 
streamlining procedures for receipt and processing of high numbers of samples, including high-
priority clinical specimens that require immediate testing (e.g., for influenza, pox viruses, rabies, 
and viral hemorrhagic fevers). 
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 In collaboration with NIH and FDA, developed a comprehensive Lyme disease serum panel to 
assist diagnostic-test developers in industry and academia in validating and achieving FDA 
clearance of new assays for the diagnosis of Lyme disease. 
 Advanced implementation of the 2011 Food Safety Modernization Act by designating five state 
health departments and their university partners—in Colorado, Florida, Minnesota, Oregon, and 
Tennessee—as Integrated Food Safety Centers of Excellence that will train food-safety 
practitioners and identify and implement best practices and policies for disease surveillance and 
outbreak response. 
 Developed a toolkit to support state and local investigations of infections transmitted via blood 
transfusions, including babesiosis, a parasitic infection carried by ticks. 
 Built local capacity for detection, reporting, and investigation of waterborne diseases by 
providing seven states with “Spark Plug” grants designed to jump-start new and innovative 
projects.  Waterborne diseases such as Legionnaires’ disease, cryptosporidiosis, and giardiasis 
cause 40,000 annual hospitalizations resulting in healthcare costs of nearly $1 billion a year.1 
 Developed tools for fast and accurate detection of infectious diseases of global public health 
importance.  Examples of activities include the following: 
- Patented innovative methods for detection of drug-resistant HIV strains and three species of 
parasites that cause human malaria 
- Received FDA approval of a dengue diagnostic test that uses molecular technology and 
instrumentation developed for the CDC Human Influenza Virus Real-Time RT-PCR 
Diagnostic Panel 
- Developed a rapid, inexpensive bedside diagnostic dipstick test to reduce the time and cost 
of diagnosing plague 
- Distributed multi-pathogen testing platforms for detection of respiratory pathogens to 
selected National Influenza Centers, Pan American Health Organization (PAHO) sites, and 
CDC Global Detection Centers.  PAHO sites in Brazil, Canada, and Chile also received tests 
for detection of a new SARS-like coronavirus that has emerged in the Middle East (Box 2). 
Examples of Ongoing Work 
 Developing a strategic roadmap to enhance U.S. public health capacity for bioinformatics, in 
accordance with the recommendations of a 2011 CDC Blue Ribbon Panel, and establishing 
training fellowships with academic partners to address future bioinformatics workforce needs. 
 Modernizing procedures for processing surveillance data provided to the National Notifiable 
Disease Surveillance System by state health departments. 
 Advancing public health use of state-of-the-art diagnostic technologies, including 
- Multi-pathogen testing platforms for the detection of viral, bacterial, and fungal agents 
- “Non-culture” technologies for detection of foodborne outbreaks and assessment of drug 
resistance 
- Whole-genome sequencing and cloud-computing for global influenza surveillance 
                                                          
1 Collier SA, Stockman LJ, Hicks LA, Garrison LE, Zhou FJ, Beach MJ.  Direct healthcare costs of selected diseases primarily or 
partially transmitted by water.  Epidemiol Infect 2012 Nov;140(11):2003–13. 
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Box 2.   Recent Outbreak Investigations and Their Public Health Implications 
Over the past year, CDC has assisted state and local health departments in investigating hundreds of 
infectious disease outbreaks, including several multistate outbreaks, as well as clusters or cases of 
unusual diseases.  CDC has also assisted ministries of health and WHO in responding to over 220 
international disease outbreaks and provided consultation and technical support to 24 Field 
Epidemiology Training Programs covering 40 countries whose staff and trainees helped respond to 
hundreds of local outbreaks. 
A few recent examples include the following: 
 A healthcare-associated outbreak of fungal meningitis affecting patients in 20 states who received 
contaminated steroid injections prepared by a compounding pharmacy in Massachusetts.  Fungal 
disease acquired by this unusual route caused epidural abscesses and other medical complications 
that, as of March 2013, have affected more than 700 patients and led to 50 deaths.  The investigation 
highlights the importance of CDC’s role in bringing together scientific experts to fill gaps in clinical 
expertise and knowledge and in supporting the state-level healthcare-associated infection (HAI) 
programs that were critical to the response. It also underscores the need for better regulation of 
compounding pharmacies. 
 Hantavirus pulmonary syndrome (HPS) among visitors to Yosemite National Park.  First identified in 
1993 in the southwestern United States, HPS is a severe, often fatal, respiratory disease carried by 
rodents.  The outbreak response in Yosemite demonstrates the importance of maintaining expertise 
in rare but highly dangerous diseases.  Unlike in the 1993 HPS outbreak, where the death rate was 
78%, in the 2012 outbreak 75% of patients survived after HPS was confirmed in the first two cases. 
 The second largest West Nile virus outbreak in the United States since the disease was first 
detected in New York City in 1999.  Thirty-eight states were affected during summer 2012, with 
three-fourths of the cases reported in Texas, Mississippi, Louisiana, South Dakota, and Oklahoma.  
Texas was at the epicenter of the outbreak, with 586 confirmed cases and 21 deaths.  This outbreak 
underscores the importance of maintaining programs for detection and control of disease-carrying 
mosquitos. 
 Emergence of an avian influenza virus infecting poultry in China that causes severe human illness.  
Within 1 month of the first reports, the avian influenza A(H7N9) strain had sickened more than 100 
people with a case-fatality ratio of more than 20%. CDC assisted the Chinese government and WHO in 
investigating the outbreak, developed diagnostic assays for the new strain, and developed candidate 
viruses to speed vaccine development.  The detection of human infection with A(H7N9)—which thus 
far has not resulted in ongoing person-to-person spread—illustrates the need to monitor the 
emergence and spread of animal influenza viruses that could have pandemic potential.  This lesson is 
further reinforced by the detection in 11 U.S. states in 2012 of more than 300 cases of mild human 
illness caused by influenza A(H3N2) variant virus, mostly associated with prolonged exposure to pigs 
at agricultural fairs. 
 Emergence in the Middle East of a novel coronavirus—distinct from the SARS coronavirus—that 
causes severe acute respiratory illness.  Through May 2013, 50 cases, including 30 deaths, have been 
reported in Saudi Arabia, Qatar, Jordan, the United Kingdom, the United Arab Emirates, France, and 
Tunisia.  Several clusters of cases, including in hospitals, have occurred, although no sustained 
person-to-person transmission has been observed.  CDC has developed real-time PCR diagnostic 
assays and deployed them to partners around the world; provided epidemiologic and laboratory 
support to WHO and the ministries of health of Saudi Arabia and Jordan; and alerted the U.S. public 
health and medical communities to prepare for possible importation of the novel virus.  This 
outbreak—like the SARS outbreak in 2003—underscores the ongoing need for international vigilance 
and cooperation to avert the spread of new and dangerous diseases. 
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- Optical mapping for faster physical mapping and genomic sequencing of the genomes of 
foodborne and waterborne pathogens 
- Pathogen discovery techniques and high-quality reference databases like MicrobeNet for 
identifying previously unknown pathogens. 
 Establishing or strengthening regional diagnostic laboratories as a cost-effective way to provide 
specialized disease-detection services and ensure laboratory surge capacity during outbreaks, 
working in partnership with state public health laboratories and the Association of Public Health 
Laboratories (APHL).  Examples include 
- Creating four molecular diagnostics reference centers for vaccine-preventable diseases (e.g., 
measles, mumps, rotavirus, pertussis, and pneumococcal disease), in California, Minnesota, 
New York, and Wisconsin 
- Partnering with public health laboratories in California, Idaho, New York, Tennessee, and 
Wisconsin that serve as state-wide and regional CaliciNet Outbreak Support Centers, to 
provide strain-typing services during foodborne disease outbreaks caused by noroviruses—
the leading cause of acute gastroenteritis in the United States.2 
 Advancing applied research on medical countermeasures against anthrax and smallpox, and 
continuing to evaluate and update recommendations for their use. 
 Providing guidance to medical and public health partners on meaningful use of electronic health 
records (EHRs) to advance CDC Winnable Battles to improve food safety and reduce HIV/AIDS 
and HAIs. 
 Upgrading state-level prevention, detection, and control of mosquito-borne and tickborne 
diseases such as West Nile virus, Lyme disease, and Rocky Mountain spotted fever.  CDC and 
state health departments have also identified two new tickborne pathogens—an Ehrlichia muris–
like agent in Minnesota and Heartland virus in Missouri—whose impact and prevention are the 
subject of ongoing study. 
 Responding to the resurgence of pertussis in the United States by providing outbreak assistance 
to affected states, establishing enhanced surveillance in six Active Bacterial Core surveillance 
(ABCs) sites, monitoring vaccine effectiveness over time in children and adolescents, and 
identifying ways to protect infants who are too young to vaccinate.  Partners include the 
Infectious Diseases Society of America (IDSA), the National Foundation for Infectious Diseases 
(NFID), the Pediatric Infectious Diseases Society (PIDS), and the HHS National Vaccine Program 
Office (NVPO). 
 Providing international partners with laboratory training to strengthen infectious disease 
detection, treatment, and control.  Examples include advancing 
- Rapid diagnosis of Ebola and other viral hemorrhagic fevers (VHFs), in partnership with the 
newly renovated VHF laboratory at the Uganda Viral Research Institute.  In 2012, the VHF 
laboratory provided diagnostic support for investigations of Ebola outbreaks in Uganda and 
the Democratic Republic of the Congo (DRC) and a Marburg outbreak in Uganda 
                                                          
2 Hall AJ, Eisenbart VG, Etingüe AL, Gould LH, Lopman BA, Parashar UD.  Epidemiology of foodborne norovirus outbreaks, United 
States 2001–2008.  Emerg Infect Dis 2012 Oct;18(10):1566–73. 
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- Use of new diagnostic tools, including 
□ The Xpert MTB/RIF test, which enables national TB programs around the world to 
identify drug resistance in TB patient samples within hours instead of weeks 
□ A rapid test for rabies that can help clinicians make life-saving decisions about whether 
to treat persons who have been bitten by dogs 
□ Molecular assays for rapid detection of dengue and other arboviral diseases by public 
health laboratories in the United States and overseas. 
Element 2. Identify and implement high-impact public health interventions to reduce 
infectious diseases 
CDC works with public and private sector partners to develop, validate, and implement high-
impact tools that can prevent and control infectious diseases within a short timeframe, reducing 
disease burden and health inequities while saving lives and reducing healthcare costs. 
Examples of ID Accomplishments 
 Advanced CDC Winnable Battles to improve food safety and reduce HIV/AIDS and healthcare-
associated infections, using proven tools and interventions (Boxes 3–5). 
 Translated new scientific findings into clinical guidance on treatment of latent tuberculosis, 
Group A streptococcal pharyngitis, and Chagas disease3 acquired via organ transplantation, 
working with professional societies and other partners. 
 Issued new recommendations for treatment of drug-resistant gonorrhea 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a3.htm) in response to increasing 
rates of drug-resistant gonorrhea detected via the Gonococcal Isolate Surveillance Project. 
 Created the CRE Toolkit, which provides step-by-step instructions for preventing carbapenem-
resistant Enterobacteriaceae (CRE), untreatable and hard-to-treat infections that are increasing 
among patients in medical facilities. 
 Developed a highly effective natural repellent and insecticide against mosquitoes and ticks and 
licensed it to commercial partners to develop products for consumer purchase. 
 Recommended that all Americans born from 1945 through 1965 be tested for hepatitis C and 
referred to care, as needed, to prevent thousands of premature deaths from cirrhosis and liver 
cancer (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm?s_cid=rr6104a1_w). 
 Provided the evidence base for Advisory Committee on Immunization Practices (ACIP) 
recommendations on administration of human papillomavirus (HPV) vaccine to boys aged 11 or 
12 years, to prevent the spread of HPV, a sexually transmitted infection that is a major cause of 
cervical cancer (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm; Box 6). 
                                                          
3 Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, Morris MI, Nowicki M, Wright C, Ison MG.  Screening 
and treatment of Chagas disease in organ transplant recipients in the United States:  Recommendations from the Chagas in 
Transplant Working Group.  Am J Transplant 2011 Apr;11(4):672–80. 
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Box 3.   CDC Winnable Battle:  Food Safety 
Forty-eight million Americans, or 1 in 6, become sick each year from contaminated food, and about 
3,000 Americans die every year because of a food-related illness.*  Better prevention and control of 
foodborne infections will not only prevent illness but also save billions of dollars in healthcare-related 
and industry costs.† 
As described in CDC Vital Signs:  Making Food Safer to Eat, CDC and partners are making food safer to 
eat by reducing contamination from such foodborne pathogens as E. coli O157, which has been 
responsible for the recall of millions of pounds of ground beef, and Salmonella, which causes more 
hospitalizations and deaths than any other type of foodborne infection.  Other foodborne illnesses of 
public health concern include norovirus infections, which are the most common cause of acute 
gastroenteritis, and toxoplasmosis, which causes an estimated 400 to 4,000 congenital infections per 
year. 
Recent actions to advance food safety include 
 Investigating more than 20 multistate foodborne disease outbreaks and tracking more than 150 
clusters of suspected food-related illness.  CDC has developed a standardized questionnaire for 
interviewing patients during foodborne or waterborne disease outbreaks.  One site that used the 
questionnaire reported an 86% drop in the time it took to interview outbreak patients, falling from 21 
days to 3 days 
 Testing more than 5,000 microbial samples collected by the National Antimicrobial Resistance 
Monitoring System—including Salmonella, Shigella, Campylobacter, E. coli, and Vibrio—to document 
emerging drug resistance in foodborne pathogens 
 Providing FDA with infectious disease data to guide development of food safety policies that fulfill 
provisions in the 2010 Food Safety Modernization Act. 
Ongoing work includes 
 Developing innovative tools, methods, and analytics that allow faster and more complete 
identification of foodborne outbreaks and their causes.  New tools include next-generation “non-
culture” tests for use by laboratories that participate in PulseNET, the nation’s outbreak detection 
system for foodborne diseases 
 Building state and local capacity to detect foodborne disease outbreaks by strengthening diagnostic 
laboratories and training partners in outbreak detection, investigation, and response 
 Tracking disease trends and sharing data with public health partners, regulatory agencies, industry, 
and the public to guide development and implementation of policies that strengthen food safety. 
More information available at http://www.cdc.gov/winnablebattles/foodsafety/index.html 
* Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson M-A, Roy SL, Jones JL, and Griffin PM.  Foodborne illness 
Acquired in the United States—major pathogens.  Emerg Infect Dis 2011 January;17(1):7–15. 
† Hoffmann S, Batz MB, Morris JG Jr.  Annual cost of illness and quality-adjusted life year losses in the United States 
due to 14 foodborne pathogens.  J Food Prot 2012 Jul;75(7):1292–302. 
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Box 4.   CDC Winnable Battle:  HIV in the United States 
Despite major advances in prevention and treatment, HIV infection remains a significant national and 
global public health challenge.  More than 1 million Americans live with HIV, and approximately 50,000 
become newly infected each year. 
In accordance with the National HIV/AIDS Strategy, CDC is pursuing a High-Impact Prevention approach 
to reducing new HIV infections that targets proven, cost-effective, and scalable interventions to high-
risk groups.  In these efforts, CDC has 
 Identified and linked 18,000 HIV-positive persons to care, by conducting nearly 2.8 million HIV tests 
as part of the Expanded HIV Testing Initiative.  This program has prevented an estimated 3,400 new 
HIV infections and achieved a return of $1.97 for every dollar invested 
 Intensified public health efforts to reach at-risk youth in minority communities, as described in CDC 
Vital Signs:  HIV Among Youth in the US:  Protecting a Generation 
 Provided clinical guidance on providing integrated prevention services for HIV infection, viral 
hepatitis, STDs, and TB among injecting-drug users and on the use of pre-exposure prophylaxis for the 
prevention of HIV infection in heterosexually active adults 
 Evaluated the best use of an FDA-approved rapid home test for HIV and developed a new assay for 
HIV-1 incidence that can be used to identify high-risk populations, target prevention efforts, and 
track the global impact of HIV prevention and treatment programs. 
Ongoing work includes 
 Implementing innovative health education campaigns sponsored by the White House and CDC, 
including Let’s Stop HIV Together—an HIV awareness and anti-stigma campaign that features 
individuals with HIV who share their personal stories 
 Supporting Care and Prevention in the United States (CAPUS) demonstration projects that expand HIV 
prevention services in communities with a high burden of disease, using individual and community-
level data to improve diagnosis, linkage to care, retention in care, and provision of antiretroviral 
therapy 
 Issuing a National HIV Prevention Report that monitors progress toward eliminating HIV/AIDS. 
More information available at http://www.cdc.gov/winnablebattles/hiv/index.html 
 Improved monitoring of the publicly funded Vaccines for Children supply chain by deploying a 
second-generation version of the CDC Vaccine Tracking System.  CDC is also implementing a 
barcoding pilot project that allows vaccine information (e.g., the manufacturer and lot number) 
to be read directly into the patient’s EHRs, in the physician’s office.  Partners include 
pharmaceutical companies, FDA, and vaccine-provider sites. 
 Worked towards an AIDS-free generation through the President’s Emergency Plan for AIDS 
Relief (PEPFAR) by supporting life-saving treatment for men, women, and children; 
antiretroviral drugs to prevent mother-to-child HIV transmission; and voluntary medical male 
circumcisions to reduce the risk of contracting HIV. 
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Box 5.   CDC Winnable Battle: Eliminating Healthcare-Associated Infections 
CDC is working to eliminate healthcare-associated infections (HAIs), using a detect and protect 
approach to detect infections, such as deadly drug-resistant pathogens, and protect patients across 
healthcare settings.  In these efforts, CDC has issued national calls to action to 
 Stop carbapenem-resistant Enterobacteriaceae (CRE), which cause hard-to-treat infections that are 
on the rise among patients in medical facilities 
 Prevent the spread of C. difficile, a healthcare-associated pathogen that causes serious diarrhea, in 
hospitals, nursing homes, and outpatient clinics. 
CDC’s National Healthcare Safety Network (NHSN) serves as the nation’s HAI tracking system, 
providing data to 
 Healthcare facilities, to monitor and prevent HAIs 
 States, to facilitate public reporting and advance regional prevention efforts 
 The Centers for Medicare and Medicaid, to ensure quality reporting from healthcare facilities 
 The Department of Health and Human Services, to measure national progress in HAI prevention. 
NHSN data document dramatic reductions in HAIs between 2008 and 2011, including a 41% reduction 
in central line-associated bloodstream infections (CLABSIs) and a 17% reduction in surgical site 
infections (SSIs).  In addition, the Emerging Infections Program reported that 26% fewer people 
developed healthcare-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) 
infections. 
CDC actions to make healthcare safer also include 
 Disseminating a CRE Toolkit that provides step-by-step instructions to healthcare facilities for 
preventing CRE 
 Helping states build capacity to monitor HAIs, respond to HAI outbreaks, and implement regional 
initiatives to improve adherence to infection control practices in healthcare settings 
 Working with key partners to implement HAI initiatives, such as HAI standards setting, state program 
and policy evaluation, education, and development of tools that help clinicians implement CDC 
guidelines. 
Ongoing work includes 
 Using NHSN data to target interventions across healthcare settings, assess the impact of HAI 
prevention activities, and support early detection of C. difficile and multidrug-resistant organisms in 
healthcare facilities 
 Working with the Healthcare Infection Control Practices Advisory Committee (HICPAC) to develop HAI 
prevention tools and guidelines that help healthcare facilities, states, and federal partners improve 
the quality of care in hospital and non-hospital settings 
 Conducting innovative research, through the Prevention Epicenters, to detect and prevent HAIs in 
specific healthcare settings and patient populations. 
A state-by-state breakdown of HAIs and reductions in infection-rates across the country can be found in 
the 2011 National and State Healthcare-associated Infections Standardized Infection Ratio Report. 
More information available at 
http://www.cdc.gov/winnablebattles/healthcareassociatedinfections/index.html 
May 2013 | 11 
 
Box 6.   The Health Impact of U.S. Vaccine Policies:  Selected Examples 
 Rotavirus.  Rotavirus vaccine has been recommended for routine use since 2006 to prevent the most 
common cause of severe diarrhea among infants and young children.   Data obtained during the 
2010–2011 rotavirus season indicate that the decline in severe rotavirus disease first documented in 
2008 has held steady,* and that babies who are vaccinated at 2–6 months exhibit no waning of 
vaccine protection through the first 3 years of life.† 
 Invasive pneumococcal disease.  In 2009, despite dramatic declines following use of pneumococcal 
conjugate vaccine 7 (PCV7), Streptococcus pneumoniae still caused an estimated 44,000 cases of 
invasive pneumococcal disease each year.  The introduction in 2010 of pneumococcal conjugate 
vaccine 13 (PVC13) further reduced invasive pneumococcal disease in children younger than 2 years 
of age (by 59%) and adults older than 65 years of age (by 28%) (CDC, unpublished data).  Over 2,000 
cases have been prevented among all ages in 10 areas that conduct active, population-based 
surveillance as part of the Emerging Infections Program. 
 Varicella (chickenpox).  Since 2006, when CDC recommended that children routinely receive a 
second dose of varicella before the age of 12, varicella infections have declined by 67–76%.‡  In 
collaboration with state and local health departments, CDC has also completed two studies that 
demonstrate high effectiveness (~ 95%) of two doses of varicella vaccine. 
 Human papillomavirus (HPV) infection.  HPV, the most common sexually transmitted infection, can 
cause cervical cancer, some other anogenital and oropharyngeal cancers, and genital warts.  Since 
mid-2006, CDC has recommended HPV vaccine for routine vaccination of girls aged 11 or 12 years 
and through age 26 years for those not previously vaccinated 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm).  In 2011, routine vaccination was 
also recommended for boys aged 11 or 12 years 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm?s_cid=mm6050a3_w).  Recent 
U.S. data have shown a decrease in genital warts§ and vaccine-type HPV prevalence among females 
aged 14–19 years,ǁ as well as a reduction in the percentage of precancerous cervical lesions due to 
vaccine-type HPV among woman who initiated vaccination at least 24 months before their diagnosis.¶ 
* Tate JE, Haynes A, Payne DC, Cortese MM, Lopman BA, Patel MM, Parashar UD. Trends in national rotavirus 
activity before and after introduction of rotavirus vaccine into the National Immunization Program in the United 
States, 2000–2012.  Pediatr Infect Dis J 2013 Feb 19 (Epub ahead of print). 
† Hoffmann S, Batz MB, Morris JG Jr.  Annual cost of illness and quality-adjusted life year losses in the United States 
due to 14 foodborne pathogens.  J Food Prot 2012 Jul;75(7):1292–302. 
‡ Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, Selvarangan R, Azimi PH, Harrison C, Moffatt M, 
Johnston SH, Sahni LC, Baker CJ, Rench MA, Donauer S, McNeal M, Chappell J, Weinberg GA, Tasslimi A, Tate JE, 
Wikswo M, Curns AT, Sulemana I, Mijatovic-Rustempasic S, Esona MD, Bowen MD, Gentsch JR, Parashar UD.  
Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of 
age, 2009-2011.  Clin Infect Dis 2013 Jul;57(1):13–20. 
§ Flagg E, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the 
United States, 2003-2010:  Potential impact of human papillomavirus vaccination.  Am J Public Health 2013 (in 
press). 
ǁ Markowitz L, Hariri S, Lin C, Dunne E, Steinau M,McQuillan C; Unger E.  Reduction in HPV prevalence among young 
women following vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 
2003–2010.  J Infect Dis 2013 (in press). 
¶ Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE.  
Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical 
lesions.  Vaccine 2012 Dec;31(1):109–13.  
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 Partnered with PAHO and ministries of health in using proven tools and procedures to 
- Ensure readiness to detect and control the mosquito-borne virus that causes Chikungunya 
fever, if this virus is imported into the Americas, as occurred with West Nile virus in 1999 
- Keep the Americas free from measles, by identifying imported cases and tracing their 
contacts.  Most cases were imported from Western Europe, which experienced outbreaks in 
2011 and 2012. 
In 2012, CDC submitted a report to PAHO documenting the continued absence of measles, 
rubella, and congenital rubella syndrome in the United States since their elimination in 2000. 
 Completed successful trials of a veterinary vaccine against Rift Valley fever, a mosquito-borne 
zoonotic disease.  Vaccination of livestock will eliminate one of the most significant sources of 
Rift Valley fever in people living in Africa and the Arabian Peninsula.   
Examples of Ongoing Work 
 Enhancing pandemic preparedness in the United States by developing candidate influenza 
strains for emergency vaccine development; exercising and evaluating CDC pandemic response 
capabilities; and updating guidance on the use of non-pharmaceutical interventions such as 
school closures and cancellation of mass gatherings.    
 Releasing updated Public Health Service Guideline for Reducing Transmission of HIV, HBV, and HCV 
through Organ Transplantation, in collaboration with professional partner organizations and other 
HHS agencies (Public Health Reports, July/August 2013). 
 Launching a joint initiative with the Veterans Health Administration (VHA) to update VHA 
procedures for prevention of healthcare-associated Legionnaires’ disease, using lessons learned 
from the response to a 2011–12 outbreak associated with VHA hospital facilities in Pittsburgh. 
 Assessing the effectiveness and cost-effectiveness of public health tools, including vaccines and 
testing procedures.  Examples include estimating the public health impact of    
- Annual influenza vaccination in preventing hospitalizations and medical visits 
- Integration of point-of-care testing for HCV into HIV programs to increase the number of 
HCV-infected persons who are referred for care.  
 Intensifying efforts to eliminate polio in the three countries where it remains endemic—Nigeria, 
Pakistan, and Afghanistan—with scientific and logistical support from the CDC Emergency 
Operations Center.  India was removed from the WHO endemic list for polio in February 2012, 
marking a major milestone in polio eradication. 
 Advancing elimination of parasitic infections that cause filariasis (transmitted by mosquitoes), 
Guinea Worm disease (transmitted through drinking water), and river blindness (transmitted by 
black flies). For example, in 2012 CDC helped the Haitian Ministry of Health complete the first 
round of nationwide mass drug treatment to eliminate filariasis. 
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Element 3. Develop and advance policies to prevent, detect, and control 
infectious diseases 
CDC facilitates development and use of effective, evidence-based policies by identifying emerging 
issues, obtaining input from groups of experts, filling data gaps, developing consensus, and 
monitoring policy implementation and impact. Policy aims include integrating clinical infectious 
disease preventive practices into U.S. healthcare; reducing health disparities; increasing individual, 
community, and clinician engagement in disease prevention efforts; and strengthening global 
capacity to detect and respond to outbreaks with the potential to cross borders. 
Examples of ID Accomplishments 
 Saved state public health departments millions of dollars through improved TB screening and 
treatment of immigrants and refugees prior to their arrival in the United States.  
 Assisted the CMS Center for Medicare and Medical Innovation in developing financial 
incentives for healthcare providers and hospitals to encourage    
- Accelerated reduction of HAIs through expanded reporting and greater adherence to 
recommended infection control practices by hospitals and other healthcare facilities 
- Faster and more complete reporting of vaccine coverage data to state immunization 
registries, through increased use of EHRs.  
 Assisted states and localities in developing administrative mechanisms that allow public health 
clinics to bill health insurance plans for immunization services for newly insured children, in 
accordance with the 2010 Affordable Care Act. 
 Updated A Public Health Action Plan to Combat Antimicrobial Resistance, which provides a policy 
blueprint for coordinated federal action.  The plan was issued by the Interagency Task Force on 
Antimicrobial Resistance, which is co-chaired by CDC, FDA, and NIH. 
 Advanced the use of mathematical modeling to support development of effective public health 
policies for disease prevention and outbreak response.  Examples include 
- Evaluating the potential impact of a vaccine against cytomegalovirus (CMV) on the U.S. 
burden of congenital CMV disease (http://www.cdc.gov/cmv/trends-stats.html).  CMV in 
newborns can cause neurologic abnormalities such as psychomotor retardation and deafness 
- Evaluating the potential impact of a novel influenza strain (H3N2v) on the U.S. population, 
in terms of illnesses, hospitalizations, and deaths, if it were to become readily transmissible 
from human to human.  Thus far, transmission has been primarily swine to human.   
 Launched a CDC Travel Health Twitter Channel (@CDCtravel) that helps U.S. residents 
traveling and/or living abroad protect themselves and their families from infectious diseases.  
CDC is also developing a mobile app that will provide access to the information in CDC Health 
Information for International Travel 2014 (The Yellow Book), working in partnership with the Oxford 
University Press. 
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 Partnered with medical experts to improve communications and ensure the accuracy of 
treatment guidance during a recent outbreak of healthcare-associated fungal meningitis.  Over 
the past year, CDC has also developed communication strategies and tools to help physicians 
- Educate parents about the benefits of ACIP-recommended childhood vaccines 
(http://www.cdc.gov/vaccines/hcp/patient-ed/conversations/index.html) 
- Educate adolescents and young adults about healthy behaviors to prevent STDs and 
promote sexual health (http://www.cdc.gov/std/sam/). 
 Established the PROTECT Initiative to keep children safe from unintentional medication 
overdoses, working with public health agencies, private sector companies, professional 
organizations, consumer/patient advocates, and academic experts. 
 Worked with international partners to strengthen global capacity for laboratory-based detection 
of infectious diseases. For example, CDC helped launch the African Society for Laboratory 
Medicine and provided technical assistance to ministries of health in the WHO/AFRO Region in 
developing National Laboratory Strategic Plans. CDC is also assisting WHO in strengthening 
disease detection and diagnosis in Cameroon, the Central African Republic, and the DRC, with 
support from the Bill and Melinda Gates Foundation 
(http://www.cdcfoundation.org/what/program/strengthening-disease-surveillance-and-
response-central-africa). 
 Helped WHO establish a global influenza vaccine donation program that in 2012 enabled the 
Lao Ministry of Health to launch its first seasonal influenza vaccination program, using vaccines 
provided by Walgreens (http://www.cdc.gov/flu/spotlights/vaccination-program-launch-
lao.htm). The program’s goal was to protect pregnant women and other persons at high risk for 
serious flu-related complications. 
Examples of Ongoing Work 
 Assessing the U.S. burden of cervical cancer preventable by HPV vaccination.   
 Working with FDA and USDA to draft a “State of the Nation” report on antimicrobial resistance 
that provides data on emerging drug-resistance issues in foodborne pathogens that can be 
transmitted from animals to humans.   CDC is also working with FDA to implement the 
Generating Antibiotic Incentives Now (GAIN) provisions of the 2012 FDA Safety and Innovation 
Act, including the establishment of antimicrobial stewardship programs and the identification of 
antimicrobial-resistant pathogens of public health significance 
(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm).  
 Evaluating strategies for improving drug therapy regimens (directly observed or self-
administered) among persons with latent TB infection, conducted by the Tuberculosis 
Epidemiologic Studies Consortium (TBESC; 
http://www.cdc.gov/tb/topic/research/TBESC/default.htm). These studies will use the new 
TBESC II Data Management System, which facilitates patient enrollment into TB research 
projects.   
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 Developing social media tools that  
- Facilitate two-way communication with individuals (especially young adults and teenagers) 
during public health emergencies (e.g., Facebook messages, blogs, and on-line surveys)   
- Allow individuals to assess their risk of acquiring viral hepatitis and other infectious 
diseases and determine whether they should be tested and/or vaccinated 
(http://www.cdc.gov/hepatitis/riskassessment/start.html and 
http://www2.cdc.gov/nip/adultimmsched/) 
- Help physicians tailor infectious disease treatment to fit the needs of specific patient 
populations (e.g., a smartphone application that provides customized recommendations for 
preventing group B streptococcus in newborns).   
 Working with swimming-pool industry representatives and public health officials to finalize a 
Model Aquatic Health Code, a set of science-based recommendations that communities can use 
to help prevent the spread of waterborne illnesses at public swimming pools, spas, and other 
man-made aquatic venues.  
 Advancing implementation of the 2005 International Health Regulations (IHR), by strengthening 
national capacities to rapidly recognize, report, and contain the spread of infectious diseases.  
Partners include ministries of health, WHO, PAHO, the Bioengagement Program of the U.S. 
Department of State, and the Defense Threat Reduction Agency of the U.S. Department of 
Defense. 
 Working with ministries of health and WHO to adapt the WHO/AFRO Integrated Disease 
Surveillance and Response system (IDSR) as a potential model for IHR implementation in Asia 
and the Middle East.    
 Working with international partners to provide the science base for global health policies that 
improve child and maternal health and increase neonatal survival rates.  Examples include 
- Evaluating the health impact and cost-effectiveness of new vaccines against rotavirus, 
pneumococcal pneumonia, and meningococcal A meningitis 
- Identifying barriers to childhood immunization and developing strategies to overcome 
them, working with ministries of health in India, Ethiopia, Indonesia, Uganda, South Sudan, 
and the DRC 
- Working with countries in the African meningitis belt (e.g., Burkina Faso, Niger, Nigeria, 
Ghana, and Mali) to enhance disease surveillance and document the effectiveness and 
impact of the new meningococcal conjugate A vaccine 
- Identifying risk factors for community-acquired infections, including drug-resistant 
infections, in young infants (http://www.chrfbd.org/ongoing-studies/) 
- Evaluating the benefits and costs of integrating immunization services with other public 
health interventions, such as distribution of bednets, vitamin A supplements, or deworming 
tablets (http://jid.oxfordjournals.org/content/205/suppl_1.toc). 
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CONCLUSION 
The accomplishments highlighted in this Progress Report illustrate ongoing progress in sustaining 
and strengthening a modern public health system that is flexible, vigilant, and ready to meet new 
challenges, including outbreaks of new and re-emerging diseases.  Moving forward, CDC and 
partners will continue to generate new ideas and make use of new knowledge, technologies, and 
alliances to strengthen public health fundamentals, implement high-impact interventions, and 
advance cost-effective policies to prevent, detect, and control infectious diseases. 
